0.00Open0.10Pre Close0 Volume81 Open Interest2.00Strike Price0.00Turnover16.06%IV0.48%PremiumFeb 21, 2025Expiry Date0.09Intrinsic Value100Multiplier64DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type0.7210Delta2.4222Gamma20.90Leverage Ratio-0.0005Theta0.0024Rho15.07Eff Leverage0.0029Vega
Brainstorm Cell Therapeutics Stock Discussion
@MARKET-TEST-DUMMY 48 hours ago.
BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology
Tuesday, 3rd December at 7:00 am
NEW YORK, Dec. 3, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it has received Notice of Allowance from the U.S. Patent & Trademark Office (USPTO) for patent applica...
No comment yet